{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:34:56Z","timestamp":1794548096343,"version":"4.9.1"},"reference-count":14,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>BI 905711, a TRAILR2\/cadherin-17 (CDH17) bispecific antibody, demonstrated preclinical apoptotic pathway activation and antitumor activity. Two phase Ia\/Ib studies tested BI 905711 monotherapy (NCT04137289) or combination therapy (NCT05087992) in advanced, refractory gastrointestinal (GI) cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Both studies aimed to determine the maximum tolerated dose (MTD; phase Ia) and recommended phase II dose (RP2D)\/recommended dose for expansion (RDE; phase Ib). In phase Ia, patients received BI 905711 monotherapy (0.02\u20134.8 mg\/kg) or 0.6 to 1.2 mg\/kg plus biweekly folinic acid (leucovorin), 5-fluorouracil, and irinotecan (FOLFIRI) and bevacizumab. Phase Ib assessed selected doses and regimens given biweekly or weekly (3 weeks on and 1 week off). Safety, efficacy, and pharmacokinetics\/pharmacodynamics were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In NCT04137289, 110 patients [median age 61 years; 80% with colorectal cancer; median of three prior therapies (range, 1\u20136)] received monotherapy. No dose-limiting toxicities (DLT) occurred, MTD was not reached, RP2D was not determined, and 48.2% of patients had treatment-related adverse events (TRAE), most commonly nausea (16.4%). In 104 response-evaluable patients, 22.1% achieved stable disease (SD). In NCT05087992, 12 patients with colorectal cancer (median age 54.5 years) received combination treatment. Two patients reported DLTs, MTD was not reached, and the selected RDE was 0.6 mg\/kg plus biweekly FOLFIRI and bevacizumab. Most patients (91.7%) had TRAEs, including decreased appetite (33.3%), alanine transaminase increased, aspartate transaminase increased, and diarrhea (25% each). Eleven patients (91.7%) achieved SD. Pharmacokinetic\/pharmacodynamic data indicated linear dose exposure and \u22652-fold activation of plasma caspase 3\/7.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In heavily pretreated patients with GI tumors, BI 905711 monotherapy or with FOLFIRI plus bevacizumab displayed a manageable safety profile and limited clinical activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Translating preclinical activity of TRAILR2 agonists into the clinic has been hampered by severe hepatotoxicity. BI 905711, a bispecific antibody against TRAILR2 and CDH17, was developed to enhance efficacy and reduce hepatotoxicity. Two phase 1 studies (NCT04137289 and NCT05087992) demonstrated tolerability and minimal hepatotoxicity, dose-proportional pharmacokinetics, and increased markers of target engagement. Antitumor activity was limited. These data show that BI 905711 has reduced TRAIL-related hepatotoxicity in the clinic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0638","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:26:50Z","timestamp":1776317210000},"page":"1123-1135","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["BI 905711, a TRAILR2\/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7029-4310","authenticated-orcid":false,"given":"James J.","family":"Harding","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 1 Department of Medicine, , New York, New York."},{"name":"2Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-8504","authenticated-orcid":false,"given":"Ralf","family":"Hofheinz","sequence":"additional","affiliation":[{"name":"3Universit\u00e4tsklinikum Mannheim, Mannheim, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-6324","authenticated-orcid":false,"given":"Elena","family":"\u00c9lez","sequence":"additional","affiliation":[{"name":"4Vall d\u2019Hebron University Hospital, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3675-953X","authenticated-orcid":false,"given":"Yasutoshi","family":"Kuboki","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rm3gk43","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Center Hospital East 5 , Kashiwa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6619-2854","authenticated-orcid":false,"given":"Drew W.","family":"Rasco","sequence":"additional","affiliation":[{"name":"6The START Center for Cancer Research, San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3504-0128","authenticated-orcid":false,"given":"Michael","family":"Cecchini","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v76x132","id-type":"ROR","asserted-by":"publisher"}],"name":"Yale University 7 Yale Cancer Center, , New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2922","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"8Peking University Cancer Hospital and Institute, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2334-8512","authenticated-orcid":false,"given":"Min","family":"He","sequence":"additional","affiliation":[{"name":"9Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2919-8819","authenticated-orcid":false,"given":"Shorena","family":"Archuadze","sequence":"additional","affiliation":[{"name":"10Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3372-6776","authenticated-orcid":false,"given":"Niraj","family":"Chhaya","sequence":"additional","affiliation":[{"name":"9Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9658-2778","authenticated-orcid":false,"given":"Franziska","family":"Haderk","sequence":"additional","affiliation":[{"name":"10Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9204-3878","authenticated-orcid":false,"given":"Lisa","family":"M\u00e9sz\u00e1ros","sequence":"additional","affiliation":[{"name":"10Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5288-9318","authenticated-orcid":false,"given":"Stefan","family":"W\u00f6lke","sequence":"additional","affiliation":[{"name":"10Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9320-7547","authenticated-orcid":false,"given":"Tetsuya","family":"Katakabe","sequence":"additional","affiliation":[{"name":"11Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6019-165X","authenticated-orcid":false,"given":"Robert M.","family":"Lorence","sequence":"additional","affiliation":[{"name":"9Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-1230","authenticated-orcid":false,"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[{"name":"12University Hospitals Gasthuisberg, University of Leuven (KUL), Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-3416","authenticated-orcid":false,"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 13 , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-480X","authenticated-orcid":false,"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 13 , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"2026051323561018700_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"key":"2026051323561018700_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026051323561018700_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026051323561018700_bib4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026051323561018700_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/BST20220098","article-title":"Therapeutic targeting of TRAIL death receptors","volume":"51","author":"Di Cristofano","year":"2023","journal-title":"Biochem Soc Trans"},{"key":"2026051323561018700_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/1535-7163.MCT-20-0253","article-title":"Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist","volume":"20","author":"Garc\u00eda-Mart\u00ednez","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026051323561018700_bib7","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00280-015-2712-0","article-title":"Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody\u00ae targeting the DR5 receptor","volume":"75","author":"Papadopoulos","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026051323561018700_bib8","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1158\/1078-0432.CCR-23-0974","article-title":"Preclinical characterization and phase I trial results of INBRX-109, a third-generation, recombinant, humanized, death receptor 5 agonist antibody, in chondrosarcoma","volume":"29","author":"Subbiah","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026051323561018700_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bbrc.2018.08.064","article-title":"Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP\/IL13 bispecific antibodies","volume":"504","author":"Venkataramani","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"2026051323561018700_bib10","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/modpathol.2008.107","article-title":"Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system","volume":"21","author":"Su","year":"2008","journal-title":"Mod Pathol"},{"key":"2026051323561018700_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1309\/AJCPKSHXI3XEHW1J","article-title":"Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2","volume":"138","author":"Panarelli","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"2026051323561018700_bib12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.canlet.2019.04.022","article-title":"Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death","volume":"454","author":"Liu","year":"2019","journal-title":"Cancer Lett"},{"key":"2026051323561018700_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00795-012-0003-y","article-title":"Involvement of liver-intestine cadherin in cancer progression","volume":"46","author":"Takamura","year":"2013","journal-title":"Med Mol Morphol"},{"issue":"13_Supplement","key":"2026051323561018700_bib14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1538-7445.AM2021-985","article-title":"Abstract 985: BI 905711 selectively induces apoptosis and anti-tumor response in TRAILR2\/CDH17\u2013expressing pancreatic cancer models","volume":"81","author":"Han","year":"2021","journal-title":"Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0638\/3772174\/crc-25-0638.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1123\/3793860\/crc-25-0638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1123\/3793860\/crc-25-0638.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:56:23Z","timestamp":1778730983000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/5\/1123\/785207\/BI-905711-a-TRAILR2-CDH17-Bispecific-Antibody"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0638","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32700275","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700311","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700251","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700272","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700302","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700293","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700281","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700305","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700227","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700239","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700212","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700245","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700224","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700257","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700266","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700287","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700233","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700209","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32700218","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8541956","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}